WIXOM, MI -- (Marketwire) -- 08/07/12 -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today its results for the second quarter ended June 30, 2012.

Second Quarter Financial Highlights

• Sales were $12.1 million compared to $11.8 million in the second quarter 2011.
• Gross profit increased $0.6 million or a 60% increase over the second quarter of 2011.
• Gross profit margins increased 5.1 percentage points to 14.2% compared to 9.1% in the second quarter of 2011.
• SG&A increased $0.5 million.
• R&D expense increased to $10.9 million compared to $3.3 million in second quarter of 2011, due to accelerated Phase III clinical development.
• Net loss was ($11.9) million compared to a net loss of ($4.5) million in second quarter of 2011, due to higher R&D expense.

First Half 2012 Financial Highlights

• Sales were $24.2 million compared to $25.1 million in the first half of 2011, due to lower sales to a single international distributor when comparing first quarter 2012 to first quarter 2011.
• Gross profit margins improved 3.1 percentage points to 13.9% compared to 10.8% in the first half of 2011.
• Gross profit dollars increased 23% or $0.6 million compared to the first half of 2011.
• SG&A increased $1.1 million due mainly to higher non-cash charges for equity compensation.
• R&D expense increased to $20.3 million compared to $5.7 million in the first half of 2011, due to the cost of Phase III clinical trial development of SFP.
• Net loss was ($22.5) million compared to a net loss of ($7.5) million in first half of 2011, due to higher R&D expense.
• Cash and cash equivalents aggregated $20.4 million as of June 30, 2012.

Current Drug Development Highlights

• Phase III CRUISE efficacy studies have completed enrollment.
• PRIME study designed to capture ESA-sparing data completed enrollment.
• Data Safety Monitoring Board recommended continuation of CRUISE studies with no modifications after 3rd review.
• Preparation for Calcitriol (vitamin-D) launch on track.
• Raymond D. Pratt, MD, hired as Chief Medical Officer.

Mr. Robert L. Chioini, Chairman and CEO, stated, "We are pleased to report solid progress this past quarter, highlighted by the completion of enrollment in our Phase III CRUISE studies. We are approximately six months from seeing data on ESA sparing from the PRIME study, our Calcitriol product launch is expected to occur first quarter 2013, and we anticipate completion of the Phase III CRUISE studies mid-year 2013. In our operating business, second quarter operating performance was solid with sales, gross profit and gross profit margins increasing significantly over last year."

Conference Call Information:
Rockwell Medical will be hosting a conference call to review its second quarter 2012 results on Tuesday, August 7, 2012 at 8:30 am ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438 or to listen to the call on the web at: http://ir.rockwellmed.com/

About Rockwell Medical:
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell's lead, late-stage investigational drug for iron therapy treatment is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron in a non-invasive, physiologic manner to dialysis patients via dialysate during their regular dialysis treatment. SFP is currently in ongoing Phase III clinical trials (CRUISE-1 and CRUISE-2) and addresses a $600M U.S. and $1B global market. Rockwell's Calcitriol (generic Active Vitamin D) injection for treating secondary hyperparathyroidism is expected to launch in Q1 2013 and addresses a $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. These products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell's operating infrastructure is a ready-made sales and distribution channel to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP, upon FDA market approval.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP's unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and SFP following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

                   ROCKWELL MEDICAL, INC. AND SUBSIDIARY

                       CONSOLIDATED INCOME STATEMENTS

     For the three and six months ended June 30, 2012 and June 30, 2011

                                (Unaudited)


                  Three Months   Three Months    Six Months     Six Months
                     Ended          Ended          Ended          Ended
                 June 30, 2012  June 30, 2011  June 30, 2012  June 30, 2011
                 -------------  -------------  -------------  -------------
Sales            $  12,124,790  $  11,802,307  $  24,153,207  $  25,093,094
Cost of Sales       10,405,991     10,731,258     20,807,932     22,370,500
                 -------------  -------------  -------------  -------------
  Gross Profit       1,718,799      1,071,049      3,345,275      2,722,594
Selling, General
 and
 Administrative      2,824,379      2,372,597      5,723,063      4,619,150
Research and
 Product
 Development        10,876,396      3,313,762     20,281,943      5,716,358
                 -------------  -------------  -------------  -------------
  Operating
   Income (Loss)   (11,981,976)    (4,615,310)   (22,659,731)    (7,612,914)
Interest and
 Investment
 Income, net            77,091         77,542        188,188        163,510
Interest Expense           456            504            709          1,105
                 -------------  -------------  -------------  -------------
  Income (Loss)
   Before Income
   Taxes           (11,905,341)    (4,538,272)   (22,472,252)    (7,450,509)
Income Tax
 Expense                     -              -              -              -
                 -------------  -------------  -------------  -------------
  Net Income
   (Loss)        $ (11,905,341) $  (4,538,272) $ (22,472,252) $  (7,450,509)
                 =============  =============  =============  =============

Basic Earnings
 (Loss) per
 Share           $        (.58) $        (.26) $       (1.12) $        (.43)


Diluted Earnings
 (Loss) per
 Share           $        (.58) $        (.26) $       (1.12) $        (.43)



                   ROCKWELL MEDICAL, INC. AND SUBSIDIARY

                        CONSOLIDATED BALANCE SHEETS

                 As of June 30, 2012 and December 31, 2011


                                               June 30, 2012   December 31,
  ASSETS                                        (Unaudited)        2011
                                               -------------  -------------
Cash and Cash Equivalents                      $   6,469,912  $   5,715,246
Investments Available for Sale                    13,915,937     11,810,775
Accounts Receivable, net of a reserve of
 $23,000 in 2012 and $29,000 in 2011               4,356,005      4,222,816
Inventory                                          2,762,089      2,504,127
Other Current Assets                               1,893,444      1,643,565
                                               -------------  -------------
  Total Current Assets                            29,397,387     25,896,529

Property and Equipment, net                        2,034,386      2,290,476
Intangible Assets                                    750,258        833,773
Goodwill                                             920,745        920,745
Other Non-current Assets                             988,231      1,998,076
                                               -------------  -------------
  Total Assets                                 $  34,091,007  $  31,939,599
                                               =============  =============


  LIABILITIES AND SHAREHOLDERS' EQUITY

Capitalized Lease Obligations                  $       3,533  $       6,470
Accounts Payable                                   6,411,007      5,364,537
Accrued Liabilities                               10,794,235      8,225,015
Customer Deposits                                    209,752         96,329
                                               -------------  -------------
  Total Current Liabilities                       17,418,527     13,692,351

Capitalized Lease Obligations                            591          2,280

  Shareholders' Equity:
Common Shares, no par value, 21,267,320 and
 18,710,002 shares issued and outstanding         88,407,885     67,407,847
Common Share Purchase Warrants, 2,376,440 and
 2,607,440 warrants issued and outstanding         6,897,948      7,103,975
Accumulated Deficit                              (78,457,994)   (55,985,742)
Accumulated Other Comprehensive Loss                (175,950)      (281,112)
                                               -------------  -------------
  Total Shareholders' Equity                      16,671,889     18,244,968
                                               -------------  -------------

  Total Liabilities And Shareholders' Equity   $  34,091,007  $  31,939,599
                                               =============  =============

                   ROCKWELL MEDICAL, INC. AND SUBSIDIARY

                   CONSOLIDATED STATEMENTS OF CASH FLOWS

          For the six months ended June 30, 2012 and June 30, 2011

                                (Unaudited)


                                                    2012           2011
                                               -------------  -------------

Cash Flows From Operating Activities:
  Net (Loss)                                   $ (22,472,252) $  (7,450,509)
  Adjustments To Reconcile Net Loss To Net
   Cash Used In
    Operating Activities:
    Depreciation and Amortization                    555,182        650,695
    Share Based Compensation - Non-employee          614,762         64,073
    Share Based Compensation - Employees           2,393,609      2,138,960
    Loss (Gain) on Disposal of Assets                 25,340         25,299

    Changes in Assets and Liabilities:
      Decrease (Increase) in Accounts
       Receivable                                   (133,189)        10,153
      Decrease (Increase) in Inventory              (257,962)       579,181
      (Increase) Decrease in Other Assets            759,966       (934,548)
      Increase (Decrease) in Accounts Payable      1,046,470       (440,717)
      Increase in Other Liabilities                2,682,643        399,522
                                               -------------  -------------
        Changes in Assets and Liabilities          4,097,928       (386,409)
                                               -------------  -------------
        Cash Provided By (Used) In Operating
         Activities                              (14,785,431)    (4,957,891)

Cash Flows From Investing Activities:
Purchase of Equipment                               (242,495)      (210,704)
Proceeds on Sale of Assets                             1,578              -
(Purchase) of Investments Available for Sale      (2,000,000)      (159,229)
                                               -------------  -------------
        Cash (Used) In Investing Activities       (2,240,917)      (369,933)

Cash Flows From Financing Activities:
  Proceeds from Issuance of Common Shares and
   Purchase Warrants                              17,785,640      2,393,317
  Payments on Notes Payable and Capital Lease
   Obligations                                        (4,626)       (10,950)
                                               -------------  -------------
        Cash Provided By Financing Activities     17,781,014      2,382,367

Increase (Decrease) In Cash                          754,666     (2,945,457)
Cash At Beginning Of Period                        5,715,246     12,263,449
                                               -------------  -------------
Cash At End Of Period                          $   6,469,912  $   9,317,992
                                               =============  =============